Global Oropharyngeal Candidiasis Market is anticipated to Witness Steady Growth owing to Rising Geriatric Population
Market Overview Oropharyngeal candidiasis, commonly known as thrush, is a fungal infection that grows in the mouth and throat caused by an overgrowth of yeast called Candida albicans. It affects infants, elderly individuals, and those with weakened immune systems. Oral thrush presents as white or yellowish lesions in the mouth and tongue that can be painful. With the growing geriatric population worldwide, the risk of this fungal infection is increasing considerably. The global oropharyngeal candidiasis market is estimated to be valued at US$ 456 MN in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period of 2024 to 2031. Key Takeaways Key players operating in The Global Oropharyngeal Candidiasis Market are Bayer AG, Teva Pharmaceuticals, Stellar Pharma, Pfizer, Wockhardt, Ranbaxy Laboratories, Bristol Laboratories, Glenmark Pharmaceuticals Ltd, and GlaxoSmithKline. The rising prevalence of HIV/AIDS and diabetes presents significant opportunities for players i...